Skip to Content
Merck
All Photos(1)

Documents

G4919

Sigma-Aldrich

Goserelin acetate

≥99% (HPLC), white, powder

Synonym(s):

[D-Ser(tBu)6,Azagly10]-LHRH acetate salt

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C59H84N18O14
CAS Number:
Molecular Weight:
1269.41
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.32

Quality Level

Assay

≥99% (HPLC)

form

powder

color

white

solubility

H2O: 20 mg/mL, clear, colorless

shipped in

dry ice

storage temp.

−20°C

SMILES string

CC(O)=O.CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O

InChI

1S/C59H84N18O14.C2H4O2/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38;1-2(3)4/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90);1H3,(H,3,4)/t38-,39-,40-,41-,42-,43-,44-,45+,46-;/m0./s1

InChI key

IKDXDQDKCZPQSZ-JHYYTBFNSA-N

Looking for similar products? Visit Product Comparison Guide

Amino Acid Sequence

Glp-His-Trp-Ser-Tyr-Ser(tBu)-Leu-Arg-Pro-azaGly-NH2

General description

Goserelin acetate is a synthetic decapaptide, which is a potent analog of LHRH (luteinizing hormone releasing hormone).
Goserelin is used to guard ovary during breast-cancer adjuvant chemotherapy.

Biochem/physiol Actions

Goserelin acetate peptide results in significant inhibition of gonadotropin release and suppresses steroidogenesis in ovaries and testis. Thus, it leads to a reduction of testosterone to castration levels and estrogen to postmenopausal levels. Therefore, this peptide is used for reducing testosterone levels in patients with locally advanced prostate cancer.
Goserelin is a synthetic analog of LHRH (leutinizing hormone releasing hormone). Goserelin is a LHRH agonist It is used in prostate cancer and breast cancer therapies and also in the treatment of endometriosis.

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

M Bolla et al.
The New England journal of medicine, 337(5), 295-300 (1997-07-31)
We conducted a randomized, prospective trial comparing external irradiation with external irradiation plus goserelin (an agonist analogue of gonadotropin-releasing hormone that reduces testosterone secretion) in patients with locally advanced prostate cancer. From 1987 to 1995, 415 patients with locally advanced
M Machluf et al.
World journal of urology, 18(1), 80-83 (2000-04-15)
Some of the most promising systems for the controlled release of bioactive agents, i.e., peptides or hormones, involve the encapsulation or entrapment of hormones or peptides in biocompatible polymeric devices that enable their continuous release over prolonged periods. In urology
Steven P Schwendeman et al.
Journal of controlled release : official journal of the Controlled Release Society, 190, 240-253 (2014-06-15)
Biodegradable, injectable depot formulations for long-term controlled drug release have improved therapy for a number of drug molecules and led to over a dozen highly successful pharmaceutical products. Until now, success has been limited to several small molecules and peptides
Andreas Lammerich et al.
Reproductive biology and endocrinology : RB&E, 13, 130-130 (2015-12-02)
XM17 is a recombinant human follicle-stimulating hormone (rhFSH) intended mainly for use in controlled ovarian hyperstimulation and the treatment of anovulation. The purpose of the current study was to establish bioequivalence, safety and tolerability of single 300-IU subcutaneous (sc) doses
Halle C F Moore et al.
The New England journal of medicine, 372(10), 923-932 (2015-03-05)
Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown mixed results and lack data on pregnancy outcomes. We randomly assigned 257 premenopausal women with operable

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service